Alphatec Holdings, Inc. $ATEC Shares Acquired by Next Century Growth Investors LLC

Key Points

• Next Century Growth Investors LLC increased its stake in Alphatec Holdings, acquiring an additional 696,585 shares, bringing their total ownership to 1,678,678 shares, representing 1.5% of their portfolio.
• Analysts have a generally positive outlook on Alphatec, with several firms issuing "buy" ratings and a current average target price set at $18.50.
• The company's stock recently opened at $16.18, showing a 27.5% revenue increase compared to the same quarter last year, despite a reported -24.33% net margin.

Next Century Growth Investors LLC increased its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 70.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,678,678 shares of the medical technology company's stock after buying an additional 696,585 shares during the period. Alphatec comprises approximately 1.5% of Next Century Growth Investors LLC's holdings, making the stock its 20th biggest holding. Next Century Growth Investors LLC owned about 1.15% of Alphatec worth $17,022,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Comerica Bank boosted its stake in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 1,248 shares during the last quarter. Quarry LP boosted its stake in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after acquiring an additional 2,375 shares during the last quarter. Larson Financial Group LLC bought a new position in Alphatec during the 1st quarter valued at $54,000. Lazard Asset Management LLC bought a new position in Alphatec during the 4th quarter valued at $76,000. Finally, State of Wyoming bought a new position in Alphatec during the 4th quarter valued at $86,000. Hedge funds and other institutional investors own 66.35% of the company's stock.

Insider Activity

In other news, COO Scott Lish sold 36,081 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $12.53, for a total value of $452,094.93. Following the completion of the transaction, the chief operating officer directly owned 708,855 shares in the company, valued at $8,881,953.15. This trade represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total transaction of $269,751.72. Following the completion of the transaction, the general counsel owned 438,331 shares of the company's stock, valued at $6,535,515.21. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 410,247 shares of company stock worth $5,376,804 over the last three months. Corporate insiders own 22.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ATEC. Barclays reiterated an "overweight" rating and set a $22.00 price objective (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Wall Street Zen downgraded shares of Alphatec from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday, June 16th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $18.50.

Alphatec Stock Performance

NASDAQ ATEC traded down $0.24 on Tuesday, hitting $15.67. The stock had a trading volume of 620,909 shares, compared to its average volume of 2,062,495. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -13.86 and a beta of 1.02. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The company's 50-day moving average is $12.98 and its two-hundred day moving average is $11.78. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $16.47.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business's revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.